Rhinovirus vaccine - Meissa Vaccines

Drug Profile

Rhinovirus vaccine - Meissa Vaccines

Latest Information Update: 23 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Meissa Vaccines
  • Developer Emory University; Meissa Vaccines
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Rhinovirus infections

Most Recent Events

  • 10 May 2017 Meissa Vaccine receives phase I SBIR grant from National Institutes of Health for rhinovirus vaccine development in Rhinovirus infections
  • 15 Jun 2016 Emory University and Children's Healthcare of Atlanta files for patent protection with the US Patent and Trademark Office for Rhinovirus vaccine in USA
  • 01 Jan 2016 Preclinical trials in Rhinovirus infections (Prevention) in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top